Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Sector ETF report for PBE
Zacks
More News
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Smart Beta ETF report for PBE
Zacks
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Sector ETF report for PBE
Zacks
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Smart Beta ETF report for PBE
Zacks
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Sector ETF report for PBE
Zacks
Why Did MNKD Stock Jump Over 7% In Pre-Market Today?
The U.S. FDA approved an update to the prescribing information for Afrezza inhalation powder to treat adults with diabetes mellitus.
Stocktwits
Inside the Recent Strength in Biotech ETFs
Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and strong deal activity fuel biotech gains.
Zacks
2 ETFs to Watch for Outsized Volume on Biotechnology Stocks
Biotech ETFs PBE and FBT saw trading volumes soar to over four times their averages, signaling rising interest amid a down day for major indexes.
Zacks
MannKind Stock Soared 8% Today: Why A Surge In Afrezza Inhaled Insulin Sales Matters
The company has now also submitted a supplementary application to the FDA for approval of Afrezza in the pediatric population aged 4-17 years.
Stocktwits
Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansion
CEO John P. Butler said that the company is “disappointed” with the outcome of its meeting with the FDA on a path forward for the design of a clinical trial of Vafseo in patients with late-stage chronic kidney disease not on dialysis.